©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessRetinitis pigmentosa, syndromal; differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Retinitis pigmentosa, syndromal, comprising 127 curated genes according to the clinical signs

ID
RP0873
Number of genes
97 Accredited laboratory test
Examined sequence length
1,7 kb (Core-/Core-canditate-Genes)
291,2 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
RPE651602NM_000329.3AD, AR
ABHD121197NM_001042472.3AR
ACO22343NM_001098.3AD, AR
ADGRV118921NM_032119.4AR, digenisch
AHI13591NM_017651.5AR
AIRE1638NM_000383.4AD, AR
ALDH3A21458NM_000382.3AR
ALMS112504NM_015120.4AR
ARL2BP492NM_012106.4AR
ARL6561NM_177976.3AR
BBS11782NM_024649.5AR, digenisch
BBS102172NM_024685.4AR
BBS122133NM_152618.3AR
BBS22166NM_031885.5AR
BBS41560NM_033028.5AR
BBS51026NM_152384.3AR
BBS72148NM_176824.3AR
BBS92664NM_198428.3AR
CC2D2A4863NM_001080522.2AR
CEP1644383NM_014956.5AR
CEP2907440NM_025114.4AR
CEP782216NM_001098802.3AR
CFAP418624NM_177965.4AR
CLN51077NM_006493.4AR
CLN6936NM_017882.3AR
CLN8861NM_018941.4AR
CLRN1699NM_174878.3AR
CNNM42328NM_020184.4AR
COL18A14560NM_001379500.1AR
COL4A15010NM_001845.6AD
CSPP13666NM_024790.6AR
CTSD1239NM_001909.5AR
CWC271883NM_005869.4AR
DHDDS900NM_001243564.2AR
ERCC64482NM_000124.4AR
ERCC81191NM_000082.4AR
FLVCR11668NM_014053.4AR
HARS11530NM_002109.6AR
HMX11047NM_018942.3AR
IFT1404389NM_014714.4AR
IFT27558NM_006860.5AR
INPP5E1945NM_019892.6AR
IQCB11797NM_001023570.4AR
KIF113171NM_004523.4AD
KLHL71761NM_001031710.3AD
LAMA19228NM_005559.4AR
LRP213968NM_004525.3AR
LZTFL1900NM_020347.4AR
MFSD81557NM_152778.3AR
MKKS1713NM_018848.3AR
MKS11680NM_017777.4AR
MTTP2685NM_000253.4AR
MYO7A6648NM_000260.4AR
NDP402NM_000266.4XL
NEUROD11071NM_002500.5AR
NPHP12202NM_000272.5AR
NPHP33993NM_153240.5AR
NPHP44281NM_015102.5AR
NR2E31234NM_014249.4AD, AR
OAT1320NM_000274.4AR
OFD13039NM_003611.3XLR
OTX2870NM_172337.3AD
PANK21713NM_153638.4AR
PCDH155868NM_033056.4AR, digenisch
PCYT1A1104NM_005017.4AR
PEX13852NM_000466.3AR
PEX2918NM_000318.3AR
PEX62943NM_000287.4AR
PEX7972NM_000288.4AR
PHYH1017NM_006214.4AR
PNPLA63984NM_006702.5AR
PPT1921NM_000310.4AR
PRPS1957NM_002764.4XL
RBP4606NM_006744.4AD, AR
RCBTB11596NM_018191.4AD, AR
RGS92025NM_003835.4AR
RHO1047NM_000539.3AD, AR
RPGR2448NM_000328.3XL
RPGRIP1L3948NM_015272.5AR
SCAPER4203NM_020843.4AR
SDCCAG82142NM_006642.5AR
SLC38A81308NM_001080442.3AR
TMEM2371227NM_001044385.3AR
TPP11692NM_000391.4AR
TTC81518NM_198309.3AR
TUB1686NM_003320.5AR
TUBGCP65460NM_020461.4AR
USH1C1659NM_005709.4AR
USH1G1386NM_173477.5AR
USH2A15609NM_206933.4AR
VCAN1968NM_004385.5 AD
VPS13B12069NM_017890.5AR
WDPCP2241NM_015910.7AR
WDR194029NM_025132.4AR
WHRN2724NM_015404.4AR
ZFYVE267620NM_015346.4AR
ZNF4233675NM_015069.5AD, AR

Informations about the disease

Clinical Comment

Retinitis Pigmentosa (RP) is the most common form of hereditary retinal dystrophy characterised by photoreceptor degeneration. RP manifests with initial night blindness and tunnel vision, followed by secondary loss of cone photoreceptors, leading to reduced visual acuity and macular degeneration. The onset and progression of RP and the severity of symptoms can vary significantly between patients, even within the same family. Autosomal recessive inherited RP is identified in more than half of all patients. Almost 200 different isolated forms of RP are currently known, either autosomal recessively or dominantly inherited. RP is less commonly comprised in syndromes that affect other organs and tissues in the body. The most common form of syndromic retinitis pigmentosa is Usher syndrome, the combination of vision and hearing loss (with balance problems), which usually starts early. RP is also a feature of several other genetic syndromes, such as Bardet-Biedl syndrome, Refsum disease and Stickler syndrome. There are often different clinical manifestations. An inconspicuous genetic finding does not mean that the suspected clinical diagnosis is excluded.

Reference: https://www.ncbi.nlm.nih.gov/books/NBK1417/

 

Synonyms
  • Alias: Retinopathia pigmentosa, syndromal
  • Allelic: Aphasia, primary progressive (GRN)
  • Allelic: Arterial calcification, generalized, of infancy, 2 (ABCC6)
  • Allelic: Bile acid synthesis defect, congenital, 4 (AMACR)
  • Allelic: Ectodermal dysplasia + immunodeficiency 1 (IKBKG)
  • Allelic: Frontotemporal lobar degeneration with ubiquitin-positive inclusions (GRN)
  • Allelic: Heimler syndrome 2 (PEX6)
  • Allelic: Immunodeficiency 33 (IKBKG)
  • Allelic: Metabolic syndrome, protection against (MTTP)
  • Allelic: Nephronophthisis 1, juvenile (NPHP1)
  • Allelic: Optic atrophy 9 (ACO2)
  • Allelic: Pseudoxanthoma elasticum, forme fruste (ABCC6)
  • Allelic: Sideroblastic anemia, B-cell immunodeficiency, periodic fevers, development delay (TRNT1)
  • Allelic: Spermatogenic failure 58 (IFT74)
  • Allelic: Type 2 diabetes mellitus, susceptibility to (NEUROD1)
  • Abetalipoproteinemia (MTTP)
  • Alpha-methylacyl-CoA racemase deficiency (AMACR)
  • Alstrom syndrome (ALMS1)
  • Arts syndrome (PRPS1)
  • Ataxia, posterior column, with retinitis pigmentosa (FLVCR1)
  • Autoimmune polyendocrinopathy syndrome, type I, +/- reversible metaphyseal dysplasia (AIRE)
  • Bardet-Biedl syndrome 1 (BBS1)
  • Bardet-Biedl syndrome 10 (BBS10)
  • Bardet-Biedl syndrome 11 (TRIM32)
  • Bardet-Biedl syndrome 12 (BBS12)
  • Bardet-Biedl syndrome 13 (MKS1)
  • Bardet-Biedl syndrome 14 (CEP290)
  • Bardet-Biedl syndrome 15 (WDPCP)
  • Bardet-Biedl syndrome 16 (SDCCAG8)
  • Bardet-Biedl syndrome 17 (LZTFL1)
  • Bardet-Biedl syndrome 18 (BBIP1)
  • Bardet-Biedl syndrome 19 (IFT27)
  • Bardet-Biedl syndrome 2 (BBS2)
  • Bardet-Biedl syndrome 21 (C8orf37)
  • Bardet-Biedl syndrome 22 (IFT74)
  • Bardet-Biedl syndrome 3 (ARL6)
  • Bardet-Biedl syndrome 4 (BBS4)
  • Bardet-Biedl syndrome 6 (MKKS)
  • Bardet-Biedl syndrome 7 (BBS7)
  • Bardet-Biedl syndrome 8 (TTC8)
  • Bardet-Biedl syndrome 9 (BBS9)
  • Boucher-Neuhauser syndrome (PNPLA6)
  • Bradyopsia (RGS9)
  • Brain small vessel disease with/-out ocular anomalies (COL4A1)
  • Cerebroretinal microangiopathy with calcifications + cysts (CTC1)
  • Ceroid lipofuscinosis, neuronal, 1 (PPT1)
  • Ceroid lipofuscinosis, neuronal, 10 (CTSD)
  • Ceroid lipofuscinosis, neuronal, 11 (GRN)
  • Ceroid lipofuscinosis, neuronal, 2 (TPP1)
  • Ceroid lipofuscinosis, neuronal, 3 (CLN3)
  • Ceroid lipofuscinosis, neuronal, 4A (Kufs type), AR (CLN6)
  • Ceroid lipofuscinosis, neuronal, 5 (CLN5)
  • Ceroid lipofuscinosis, neuronal, 6 (CLN6)
  • Ceroid lipofuscinosis, neuronal, 7 (MFSD8)
  • Ceroid lipofuscinosis, neuronal, 8 (CLN8)
  • Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant (CLN8)
  • Cockayne syndrome, type A (ERCC8)
  • Cockayne syndrome, type B (ERCC6)
  • Cohen syndrome (VPS13B)
  • Cone-rod dystrophy and hearing loss (CEP78)
  • Cone-rod dystrophy and hearing loss 2 (CEP250)
  • Congenital disorder of glycosylation, type 1bb (DHDDS)
  • Donnai-Barrow syndrome (LRP2)
  • Ectodermal dysplasia, ectrodactyly + macular dystrophy (CDH3)
  • Enhanced S-cone syndrome (NR2E3)
  • Foveal hypoplasia 2, with/-out optic nerve misrouting and/or anterior segment dysgenesis (SLC38A8)
  • Gyrate atrophy of choroid + retina with/-out ornithinemia (OAT)
  • HARP syndrome (PANK2)
  • Hardikar syndrome (MED12)
  • Hypotaurinemic retinal degeneration + cardiomyopathy (SLC6A6)
  • Hypotrichosis, congenital, with juvenile macular dystrophy (CDH3)
  • Incontinentia pigmenti (IKBKG)
  • Infantile cerebellar-retinal degeneration (ACO2)
  • Intellectual developmental disorder + retinitis pigmentosa (SCAPER)
  • Jalili syndrome (CNNM4)
  • Joubert syndrome 1 (INPP5E)
  • Joubert syndrome 10 (OFD1)
  • Joubert syndrome 14 (TMEM237)
  • Joubert syndrome 19 (ZNF423)
  • Joubert syndrome 2 (TMEM216)
  • Joubert syndrome 20 (TMEM231)
  • Joubert syndrome 21 (CSPP1)
  • Joubert syndrome 28 (MKS1)
  • Joubert syndrome 3 (AHI1)
  • Joubert syndrome 35 (ARL3)
  • Joubert syndrome 39 (TMEM218)
  • Joubert syndrome 4 (NPHP1)
  • Joubert syndrome 40 (IFT74)
  • Joubert syndrome 5 (CEP290)
  • Joubert syndrome 7 (RPGRIP1L)
  • Joubert syndrome 8 (ARL13B)
  • Joubert syndrome 9 (CC2D2A)
  • Knobloch syndrome, type 1 (COL18A1)
  • Laurence-Moon syndrome (PNPLA6)
  • Linear skin defects with multiple congenital anomalies 1 (HCCS)
  • Lujan-Fryns syndrome (MED12)
  • Macular dystrophy with central cone involvement (MFSD8)
  • Maturity-onset diabetes of the young 6 (NEUROD1)
  • Meckel syndrome 11 (TMEM231)
  • Meckel syndrome 2 (TMEM216)
  • Methylmalonic aciduria and homocystinuria, cblC type (MMACHC)
  • Microcephaly + chorioretinopathy, AR, 2 (PLK4)
  • Microcephaly + chorioretinopathy, AR, 3 (TUBGCP4)
  • Microcephaly and chorioretinopathy, AR, 1 (TUBGCP6)
  • Microcephaly with or without chorioretinopathy, lymphedema or mental retardation (KIF11)
  • Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation (KIF11)
  • Microcornea, myopic chorioretinal atrophy, telecanthus (ADAMTS18)
  • Morbid obesity and spermatogenic failure (CEP19)
  • Mucolipidosis III gamma (GNPTG)
  • Muscular dystrophy-dystroglycanopathy (cong. with brain + eye anomalies), type A, 3 (POMGNT1)
  • Muscular dystrophy-dystroglycanopathy (cong. with mental retardation), type B, 3 (POMGNT1)
  • Muscular dystrophy-dystroglycanopathy, limb-girdle, type C, 3 (POMGNT1)
  • Myopathy, mitochondrial, and ataxia (MSTO1)
  • Nephronophthisis 13 (WDR19)
  • Nephronophthisis 14 (ZNF423)
  • Nephronophthisis 15 (CEP164)
  • Nephronophthisis 2, infantile (INVS)
  • Nephronophthisis 3 (NPHP3)
  • Nephronophthisis 4 (NPHP4)
  • Norrie disease (NDP)
  • Oculoauricular syndrome (HMX1)
  • Ohdo syndrome, XL (MED12)
  • Oliver-McFarlane syndrome (PNPLA6)
  • Opitz-Kaveggia syndrome (MED12)
  • PERCHING syndrome (KLHL7)
  • Peroxisome biogenesis disorder 1A, Zellweger (PEX1)
  • Peroxisome biogenesis disorder 4A, Zellweger (PEX6)
  • Peroxisome biogenesis disorder 4B (PEX6)
  • Peroxisome biogenesis disorder 5A, Zellweger (PEX2)
  • Peroxisome biogenesis disorder 9B (PEX7)
  • Persistent hyperplastic primary vitreous, AR (ATOH7)
  • Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa + cataract (ABHD12)
  • Poretti-Boltshauser syndrome (LAMA1)
  • Pseudoxanthoma elasticum (ABCC6)
  • ROSAH syndrome (ALPK1)
  • Refsum disease (PHYH)
  • Retinal dystrophy + obesity (TUB)
  • Retinal dystrophy with leukodystrophy (ABCD5)
  • Retinal dystrophy with/-out extraocular anomalies (RCBTB1)
  • Retinal dystrophy, early-onset, with/-out pituitary dysfunction (OTX2)
  • Retinal dystrophy, iris coloboma + comedogenic acne syndrome (RBP4)
  • Retinal dystrophy, juvenile cataracts + short stature syndrome (RDH11)
  • Retinitis pigmentosa + erythrocytic microcytosis (TRNT1)
  • Retinitis pigmentosa 4, AD/AR (RHO)
  • Retinitis pigmentosa 7 + digenic form (PRPH2)
  • Retinitis pigmentosa 76 (POMGNT1)
  • Retinitis pigmentosa 80 (IFT140)
  • Retinitis pigmentosa 83 (ARL3)
  • Retinitis pigmentosa 87 with choroidal involvement (RPE65)
  • Retinitis pigmentosa with/-out situs inversus (ARL2BP)
  • Retinitis pigmentosa with/-out skeletal anomalies (CWC27)
  • Retinitis pigmentosa, XL + sinorespiratory infections, with/-out deafness (RPGR)
  • Senior-Loken syndrome 1 (NPHP1)
  • Senior-Loken syndrome 4 (NPHP4)
  • Senior-Loken syndrome 5 (IQCB1)
  • Senior-Loken syndrome 6 (CEP290)
  • Senior-Loken syndrome 7 (SDCCAG8)
  • Senior-Loken syndrome 8 (WDR19)
  • Senior-Loken syndrome 9 (TRAF3IP1)
  • Short-rib thoracic dysplasia 9 with/-out polydactyly [+ retinal pigment dystrophy] (IFT140)
  • Sjogren-Larsson syndrome (ALDH3A2)
  • Spastic paraplegia 15, AR (ZFYVE26)
  • Spastic paraplegia 39, AR (PNPLA6)
  • Spondylometaphyseal dysplasia with cone-rod dystrophy (PCYT1A)
  • Stickler syndrome, type IV (COL9A1)
  • Usher syndrome, type 1B (MYO7A)
  • Usher syndrome, type 1C (USH1C)
  • Usher syndrome, type 1D/F digenic (PCDH15)
  • Usher syndrome, type 1F (PCDH15)
  • Usher syndrome, type 1G (USH1G)
  • Usher syndrome, type 2A (USH2A)
  • Usher syndrome, type 2C (ADGRV1)
  • Usher syndrome, type 2C, GPR98/PDZD7 digenic (ADGRV1)
  • Usher syndrome, type 2D (WHRN)
  • Usher syndrome, type 3A (CLRN1)
  • Usher syndrome, type 3B (HARS)
  • Usher syndrome, type IJ (CIB2)
  • Wagner syndrome 1 (VCAN)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
  • digenisch
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.